We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ITUB4:BMFBOVESPAItau Unibanco Holding SA Pfd Analysis

Data as of 2026-05-21 - not real-time

R$39.83

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

ITUB4 is trading at BRL 39.83, just above the calculated support level of BRL 38.70, indicating limited downside cushion. The 20‑day SMA (BRL 41.46) sits above the current price while the 200‑day SMA (BRL 40.44) is also higher, suggesting a short‑term pullback within a longer‑term neutral bias. Technical momentum is mixed: the MACD histogram is negative and the signal line is bearish, yet the RSI at 37 points to a modest oversold condition. Valuation metrics are compelling, with a trailing P/E of 9.7 versus an industry average of 16.6, positioning the stock as potentially undervalued. The dividend yield of 1.38 % and a payout ratio of 75 % reflect a sustainable income stream supported by strong operating margins (33 %). Recent earnings commentary highlighted a 10 % YoY rise in net income, reinforcing earnings momentum despite a slight revenue contraction.
Risk indicators show a beta of roughly 0.81, indicating lower volatility than the broader market, while the 30‑day price volatility of 25.7 % remains moderate for a Brazilian bank. The Fear & Greed Index sits at 90.5 (Extreme Greed), implying bullish market sentiment that could further lift the stock. Upside potential is estimated at around 22 % based on target prices averaging BRL 48.8, offering a sizable margin of safety above current levels. However, exposure to Brazilian macro‑economic conditions, regulatory oversight, and BRL currency fluctuations introduces medium‑level geographic and currency risk. Liquidity appears robust, with daily volumes exceeding 10 million shares and average volumes well above 30 million, mitigating execution concerns. Overall, the combination of attractive valuation, resilient earnings, and solid dividend sustainability makes ITUB4 a compelling candidate for investors with a medium‑to‑long‑term horizon.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near support with limited upside
  • Bearish MACD signal
  • Moderate volatility and beta

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued relative to peers (P/E 9.7 vs 16.6)
  • Strong earnings momentum (+10% YoY net income)
  • Attractive dividend yield with sustainable payout

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Robust balance sheet and cash position
  • Long‑term upside potential (~22% to target price)
  • Stable dividend policy supporting total return

Key Metrics & Analysis

Financial Health

Revenue Growth-2.10%
Profit Margin33.28%
P/E Ratio9.7
ROE21.82%
ROA1.57%
P/B Ratio2.1
Op. Cash FlowR$21.2B
Industry P/E16.6

Technical Analysis

TrendNeutral
RSI37.3
SupportR$38.70
ResistanceR$45.12
MA 20R$41.46
MA 50R$42.93
MA 200R$40.44
MACDBearish
VolumeIncreasing
Fear & Greed Index90.46

Valuation

Target PriceR$48.77
Upside/Downside22.44%
GradeUndervalued
TypeValue
Dividend Yield1.38%

Risk Assessment

Beta0.81
Volatility25.68%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.